Parkinson disease

被引:694
|
作者
Balestrino, R. [1 ]
Schapira, A. H., V [2 ]
机构
[1] Univ Turin, Dept Neurosci, Turin, Italy
[2] UCL, Dept Clin & Movement Neurosci, Queen Sq Inst Neurol, UCL Royal Free Campus,Rowland Hill St, London NW3 2PF, England
关键词
clinical; genetics; movement disorders; neurodegeneration; Parkinson disease; pathophysiology; treatment; LEVODOPA-INDUCED DYSKINESIA; NURSING-HOME PLACEMENT; QUALITY-OF-LIFE; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; LEWY BODY; ATYPICAL PARKINSONISM; DIAGNOSTIC-CRITERIA; MOTOR FLUCTUATIONS; NONMOTOR SYMPTOMS;
D O I
10.1111/ene.14108
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%-15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded alpha -synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 50 条
  • [31] A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review
    Khan, Muhammad Adnan
    Quadri, Syed A.
    Tohid, Hassaan
    BULLETIN OF THE MENNINGER CLINIC, 2017, 81 (01) : 53 - 105
  • [32] The Genetics of Parkinson Disease
    Bekris, Lynn M.
    Mata, Ignacio F.
    Zabetian, Cyrus P.
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2010, 23 (04) : 228 - 242
  • [33] Lateralisation in Parkinson disease
    Riederer, P.
    Jellinger, K. A.
    Kolber, P.
    Hipp, G.
    Sian-Hulsmann, J.
    Krueger, R.
    CELL AND TISSUE RESEARCH, 2018, 373 (01) : 297 - 312
  • [34] Sleep disorders and Parkinson disease; lessons from genetics
    Gan-Or, Ziv
    Alcalay, Roy N.
    Rouleau, Guy A.
    Postuma, Ronald B.
    SLEEP MEDICINE REVIEWS, 2018, 41 : 101 - 112
  • [35] Prospects for Disease Slowing in Parkinson Disease
    Menozzi, Elisa
    Schapira, Anthony H. V.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2025, 65 : 237 - 258
  • [36] Exosomes in Parkinson disease
    Pinnell, Jennifer R.
    Cui, Mei
    Tieu, Kim
    JOURNAL OF NEUROCHEMISTRY, 2021, 157 (03) : 413 - 428
  • [37] Neuropathology of Parkinson disease
    Dickson, Dennis W.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : S30 - S33
  • [38] Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease
    von Coelln, Rainer
    Shulman, Lisa M.
    CURRENT OPINION IN NEUROLOGY, 2016, 29 (06) : 727 - 734
  • [39] Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
    Fleming, Sheila M.
    Ekhator, Osunde R.
    Ghisays, Valentins
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2013, (76):
  • [40] Gut bacterial composition in a mouse model of Parkinson's disease
    Perez-Pardo, P.
    Dodiya, H. B.
    Engen, P. A.
    Naqib, A.
    Forsyth, C. B.
    Green, S. J.
    Garssen, J.
    Keshavarzian, A.
    Kraneveld, A. D.
    BENEFICIAL MICROBES, 2018, 9 (05) : 799 - 814